Treace Medical Concepts, Inc. (TMCI) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite a decline in revenue and widening losses, the company has demonstrated effective cash management and cost reduction. The upcoming product launches and market expansion plans could positively impact future growth. However, persistent ASP headwinds and competitive pressures present risks. The Q&A session revealed mixed sentiments, with management providing optimistic guidance but avoiding specifics on market penetration. Given the balance of positive and negative factors, the stock price is likely to remain stable in the near term, resulting in a neutral sentiment.
Key Financial Performance
Revenue $47.2 million in Q1 2026, a decrease of 10% year-over-year. The decline was mainly driven by the shift in revenue mix towards lower-priced minimally invasive products and lower volume of bunion procedure kits sold.
Gross Margin 79.3% in Q1 2026 compared to 79.7% in Q1 2025, a slight decrease due to changes in product mix.
Total Operating Expenses $54.6 million in Q1 2026 compared to $57.5 million in Q1 2025, a decrease reflecting cost management efforts.
Net Loss $18 million or $0.28 per share in Q1 2026 compared to $15.9 million or $0.25 per share in Q1 2025, an increase in loss due to lower revenue and higher adjusted EBITDA loss.
Adjusted EBITDA Loss of $5.5 million in Q1 2026 compared to a loss of $3.8 million in Q1 2025, reflecting increased operational investments.
Cash, Cash Equivalents, and Marketable Securities $51.9 million as of March 31, 2026, an increase of $3.5 million from December 31, 2025, due to improved cash management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Bunion Systems: Three new bunion systems (Nanoplasty, Percuplasty 3D MIS Systems, and SpeedMTP Great Toe Fusion System) were launched in 2025, targeting broader market segments and increasing market penetration. These systems address challenges in bunion procedures and expand the accessible market.
Lapiplasty Lightning: A next-generation Lapiplasty platform with enhanced precision and faster procedure capabilities is set to launch later in 2026.
SuperBite Compression Screws and SpeedXM Fusion System: New products aimed at expanding procedural access and improving outcomes for midfoot and hindfoot fusion procedures. Full commercialization expected in Q3 2026.
Market Expansion: The new bunion systems and additional product offerings have expanded the total addressable market by approximately $300 million. The company is targeting broader procedural adjacencies and increasing wallet share.
Revenue Decline: Revenue in Q1 2026 was $47.2 million, a 10% decrease compared to Q1 2025, attributed to a shift towards lower-priced products and reduced kit volumes.
Cash Management: Cash, cash equivalents, and marketable securities increased to $51.9 million as of March 31, 2026, with a reduction in cash usage expected by 50% for the full year 2026.
Strategic Initiatives: Focus on leveraging existing customer base, advancing leadership in Lapiplasty, and expanding product offerings to grow wallet share and procedural access.
Market Penetration: Approximately 35% of Lapiplasty surgeon users have adopted at least one of the new bunion systems, up from 25% in Q4 2025.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: The company reported a 10% revenue decline in Q1 2026 compared to the prior year, driven by a shift in revenue mix towards lower-priced minimally invasive products and lower volume of bunion procedure kits sold.
Macroeconomic Pressures: Macroeconomic pressures on procedure demand and portfolio mix shifts that impacted 2025 remain present, potentially affecting revenue and growth.
Profitability Challenges: The company reported a net loss of $18 million in Q1 2026, an increase from the $15.9 million loss in Q1 2025. Adjusted EBITDA loss also widened to $5.5 million from $3.8 million in the prior year.
Cash Flow Concerns: Although cash burn has been reduced, the company is still progressing towards cash flow breakeven, indicating ongoing financial strain.
Market Penetration Risks: The success of new product launches and deeper market penetration is critical for growth, but adoption rates and competitive pressures could pose challenges.
Product Mix Shift: The shift towards lower-priced products has negatively impacted revenue and could continue to do so if not balanced with higher-margin offerings.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: Reaffirmed full-year 2026 revenue guidance of $202 million to $212 million, representing a decline of 5% to 0% compared to full-year 2025.
Revenue Growth Expectations: Revenue declines are expected to improve through the year, with growth anticipated in the seasonally strongest fourth quarter, supported by case volume growth, ASP mix stabilization, and contributions from planned 2026 product launches.
Product Launches: Planned commercialization of Lapiplasty Lightning, SuperBite screws, and SpeedXM Fusion System in 2026, targeting expanded market opportunities and procedural adjacencies.
Market Penetration: Continued focus on driving adoption of three new bunion systems launched in 2025, with increasing penetration among existing and new surgeon customers.
Profitability Outlook: Expected adjusted EBITDA loss of $4 million to $6 million for full-year 2026, compared to a loss of $3.9 million in 2025. Anticipated 50% reduction in cash usage for 2026 compared to 2025.
Revenue Guidance: Reaffirmed full-year 2026 revenue guidance of $202 million to $212 million, representing a decline of 5% to 0% compared to full-year 2025.
Revenue Growth Expectations: Revenue declines are expected to improve through the year, with growth anticipated in the seasonally strongest fourth quarter, supported by case volume growth, ASP mix stabilization, and contributions from planned 2026 product launches.
Profitability Outlook: Expected adjusted EBITDA loss of $4 million to $6 million for full-year 2026, compared to a loss of $3.9 million in 2025. Anticipated 50% reduction in cash usage for 2026 compared to 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the expectation for ASP headwinds and their impact throughout the year?
A:Mark Hair explained that the ASP headwinds are expected to persist until the third quarter of the year, as the company laps the anniversary of launching new products with lower ASPs. These headwinds are anticipated to ease in the back half of the year.
Q:How should gross margins be expected to trend with the launch of new products?
A:Mark Hair stated that the company aims to maintain consistent gross margins in the high 70% range, despite fluctuations from quarter to quarter. He noted that Q1 gross margins were strong and slightly better than anticipated.
Q:What is the adoption trend for the new osteotomy solutions versus Lapiplasty?
A:John Treace mentioned that 35% of the customer base has adopted the new solutions, and the company is working to increase adoption of the full portfolio. He noted that the new products are not replacing Lapiplasty but are additive, providing more options for surgeons.
Q:What percentage of foot and ankle cases could Treace products potentially address?
A:John Treace stated that it is difficult to specify an exact percentage, but the broad portfolio, including new products like SuperBite, allows the company to cover a significant portion of surgeons' foot and ankle cases.
Q:How does the SuperBite system compare to competitors in terms of SKUs?
A:John Treace explained that the SuperBite system was designed to be capital-efficient with around 100 SKUs, compared to competitors' systems that may have hundreds or even 1,000 SKUs.
Q:What is the sales cadence outlook for this year and the setup for 2027?
A:John Treace and Mark Hair highlighted that ASP-related headwinds will ease in Q3, and new product launches with favorable ASPs will contribute to growth in Q3 and Q4. They expect to return to revenue growth in Q4 and anticipate increased momentum for 2027, though no formal guidance has been provided.
Q:What is the general market environment for elective procedures?
A:John Treace noted that the macro headwinds and consumer sentiment impacts on elective procedures have continued as expected. Q1 patient flow and surgeon activity were in line with expectations.
Q:How has Lapiplasty trended recently, and what is its outlook?
A:John Treace stated that Lapiplasty continues to see strong demand where indicated, with some pull-through from surgeons adopting new products. Advancements like Lapiplasty Lightning and SpeedTMT are expected to appeal to more surgeons later this year.
Q:What are the competitive dynamics and positioning for Treace's new MIS osteotomy products?
A:John Treace explained that initial adoption was higher among existing customers, but competitive conversions have increased as the products gained traction. The company's expertise, training, and product efficacy have driven adoption and displacement of competitors.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to the question about the exact percentage of foot and ankle cases that Treace products could address, stating that it is difficult to specify an exact percentage.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ASP
Fusion System
MTP joint
SuperBite screw
access procedure
adoption
approach
biologics
bone
case volume
category
commercialization
compression screw
customer base
day
decline
fixation
fusion procedure
innovation
market penetration
market share
midfoot hindfoot
mix shift
offering
penetration product
plane
product procedure
sale force
segment
share gain
surgeon user
system technology
uptake
wallet share
TMCI Transcript
Treace Medical Concepts, Inc. (TMCI) Q1 2026 Earnings Call Transcript
Unknown5-8
Despite a decline in revenue and widening losses, the company has demonstrated effective cash management and cost reduction. The upcoming product launches and market expansion plans could positively impact future growth. However, persistent ASP headwinds and competitive pressures present risks. The Q&A session revealed mixed sentiments, with management providing optimistic guidance but avoiding specifics on market penetration. Given the balance of positive and negative factors, the stock price is likely to remain stable in the near term, resulting in a neutral sentiment.
Treace Medical Concepts, Inc. (TMCI) Q4 2025 Earnings Call Transcript
Unknown2-27
The earnings call reveals mixed signals. While the company shows improved financial health, with reduced losses and cash use, and has a strong product pipeline, the market is facing softness and uncertainties. Although there is optimism about new product adoption and sales force expansion, the guidance remains cautious, reflecting macroeconomic headwinds. Furthermore, management's lack of clarity on long-term growth rates adds to uncertainty. The positive aspects are balanced by potential risks, leading to a neutral sentiment.
Treace Medical Concepts, Inc. (TMCI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Treace Medical Concepts, Inc. (TMCI) Q3 2025 Earnings Call Transcript
Unknown11-7
The earnings call presents mixed signals: while revenue and adjusted EBITDA show improvement, the net loss has increased, and the core Lapiplasty business is facing challenges due to shifting preferences towards minimally invasive procedures. Additionally, management's refusal to provide 2026 guidance and reliance on general optimism without specifics raises concerns. The decrease in gross margin and increased operating expenses further contribute to a negative sentiment, despite progress in profitability and liquidity management.
TMCI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
